RAY 121
Alternative Names: RAY-121Latest Information Update: 26 Jul 2024
At a glance
- Originator Chugai Pharmaceutical
- Class Antibodies
- Mechanism of Action Complement system protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders; Immunological disorders
Most Recent Events
- 10 Jun 2024 Phase-I clinical trials in Immunological disorders in Japan (Parenteral) (NCT06371417)
- 23 Apr 2024 Chugai Pharmaceutical plans a phase Ib RAINBOW trial for Immunological disorders in USA and Japan (Parenteral), in May 2024 (NCT06371417)
- 22 Feb 2023 Phase-I clinical trials in Autoimmune disorders (In Volunteers) (Parenteral), before February 2023 (Chugai pharmaceuticals pipeline, February 2023)